EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic Implications of Myositis‐Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients

Ying Hou, Xiaotian Ma, Haoran Mu iD, Bing Zhao, Guoyong Zhang, Qingsong Fu, Fengyi Zhang, Xuehan Wu, Lining Zhang, Fang Wang, Wenchen Sui, Shuangwu Liu und 5 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Ying Hou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University, Shandong Provincia…. Hauptthemen laut MEDLINE: Dermatomyositis, Autoantibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To explore the clinicopathological features and treatment prognosis including death, relapse and remission of dermatomyositis (DM) based on myositis‐specific autoantibody (MSAs) stratification.

Methods

Patients with DM come from a provincial neuromuscular center in northern China. Patients who underwent biopsy from 2010 to 2023 were collected, and the follow‐up time was all more than 6 months. Clinical characteristics, serum samples, and muscle biopsies were collected. Kaplan–Meier analysis, Cox regression, and competing risk model were used for analysis.

Results

Our study included 140 patients with DM. Among the 25 juvenile patients, 9 (36%) were anti‐NXP2 antibody positive. About 80.95% of the patients with anti‐TIF1‐γ antibodies had neck flexion weakness. Patients with anti‐Mi‐2 antibodies showed a predominance of severe muscle fiber necrosis/regeneration (76.19%) rather than perifascicular atrophy (14.29%). Compared to the seronegative subgroup, the short‐ and long‐term risks of death were higher in anti‐TIF1‐γ‐positive patients, and the 3‐year risk of death was higher in anti‐MDA5 patients. The short‐ and long‐term dangers of relapse were consistently higher in anti‐Mi‐2‐positive patients, with a higher 3‐year relapse risk in the anti‐NXP2 subgroup. In the case of death as a competing risk of relapse, patients with anti‐Mi‐2 and patients with anti‐NXP2 had higher short‐ and long‐term risks of relapse. No difference was found in the clinical remission rate based on the DM‐MSA stratification.

Conclusion

Evaluating the characteristics and prognosis of DM subgroups based on serum MSA stratification is helpful for patient management and treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisAutoantibodiesHumansMaleFemalePrognosisRecurrenceAdultMiddle AgedYoung AdultAdolescentChildTranscription Factors

Stichwörter der Autor:innen

deathdermatomyositismyositis‐specific autoantibodiesrelapseremission

Substanzen

AutoantibodiesTranscription Factors

Autor:innen und Institutionen

  • Department of Neurology, Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University, Shandong Provincial Key Laboratory of Mitochondrial Medicine and Rare Diseases, Jinan, S…
  • Laboratory of Cerebrospinal Fluid Cytology and Neuroimmunology, Department of Central Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
  • Department of Neurology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
  • Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
  • Department of Rheumatology, Qilu Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
  • Department of Laboratory Medicine, Qilu Hospital, Shandong University, Jinan, Shandong, People's Republic of China.

ORCID-Profile: Haoran Mu, Kai Shao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Hou, Y., Ma, X., Mu, H., Zhao, B., Zhang, G., Fu, Q., Zhang, F., Wu, X., Zhang, L., Wang, F., Sui, W., Liu, S., Li, W., Zhao, Y., Yan, C., Dai, T., & Shao, K. (2025). Prognostic Implications of Myositis‐Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients. European Journal of Neurology. https://doi.org/10.1111/ene.70446

Vancouver

Hou Y, Ma X, Mu H, Zhao B, Zhang G, Fu Q, et al. Prognostic Implications of Myositis‐Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients. European Journal of Neurology. 2025. doi:10.1111/ene.70446

BibTeX
@article{Hou2025,
  author = {Hou, Ying and Ma, Xiaotian and Mu, Haoran and Zhao, Bing and Zhang, Guoyong and Fu, Qingsong and Zhang, Fengyi and Wu, Xuehan and Zhang, Lining and Wang, Fang and Sui, Wenchen and Liu, Shuangwu and Li, Wei and Zhao, Yuying and Yan, Chuanzhu and Dai, Tingjun and Shao, Kai},
  title = {Prognostic Implications of Myositis‐Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70446}
}
Kostenlos starten →